IL140858A0 - Endogenous constitutively activated g protein-coupled orphan receptors - Google Patents
Endogenous constitutively activated g protein-coupled orphan receptorsInfo
- Publication number
- IL140858A0 IL140858A0 IL14085899A IL14085899A IL140858A0 IL 140858 A0 IL140858 A0 IL 140858A0 IL 14085899 A IL14085899 A IL 14085899A IL 14085899 A IL14085899 A IL 14085899A IL 140858 A0 IL140858 A0 IL 140858A0
- Authority
- IL
- Israel
- Prior art keywords
- protein
- constitutively activated
- orphan receptors
- endogenous constitutively
- coupled orphan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL16044699A IL160446A0 (en) | 1998-07-31 | 1999-07-30 | Endogenous constitutively activated g protein-coupled orphan receptors |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9487998P | 1998-07-31 | 1998-07-31 | |
| US10630098P | 1998-10-30 | 1998-10-30 | |
| US11090698P | 1998-12-04 | 1998-12-04 | |
| US12185199P | 1999-02-26 | 1999-02-26 | |
| PCT/US1999/017425 WO2000006597A2 (en) | 1998-07-31 | 1999-07-30 | Endogenous constitutively activated g protein-coupled orphan receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL140858A0 true IL140858A0 (en) | 2002-02-10 |
Family
ID=27492754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14085899A IL140858A0 (en) | 1998-07-31 | 1999-07-30 | Endogenous constitutively activated g protein-coupled orphan receptors |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1095275B1 (xx) |
| JP (1) | JP2002521681A (xx) |
| CN (1) | CN1231762C (xx) |
| AT (1) | ATE432472T1 (xx) |
| AU (1) | AU751080B2 (xx) |
| CA (1) | CA2338543C (xx) |
| DE (1) | DE69940923D1 (xx) |
| DK (1) | DK1095275T3 (xx) |
| IL (1) | IL140858A0 (xx) |
| MX (1) | MXPA01001176A (xx) |
| NO (1) | NO20010509L (xx) |
| NZ (1) | NZ509429A (xx) |
| WO (1) | WO2000006597A2 (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| EP1301594A2 (en) | 2000-04-07 | 2003-04-16 | Arena Pharmaceuticals, Inc. | Non-endogenous, consstitutively activated known g protein-coupled receptors |
| AU2003218234A1 (en) * | 2002-03-15 | 2003-09-29 | Arena Pharmaceuticals, Inc. | Methods of expressing non-endogenous g protein coupled receptors in cells |
| WO2003081256A2 (en) * | 2002-03-22 | 2003-10-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21) |
| AU2003266238A1 (en) * | 2002-08-05 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1) |
| WO2004056869A1 (en) * | 2002-12-20 | 2004-07-08 | 7Tm Pharma A/S | Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| WO2005095990A1 (en) * | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507518A (ja) * | 1995-06-07 | 1999-07-06 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｇ蛋白質とカップルしたレセプターのアゴニスト及びアンタゴニストの機能的バイオアッセイ |
| EP0862614A1 (en) * | 1995-09-20 | 1998-09-09 | Molecular Geriatrics Corporation | Yeast receptor and g-protein fusion protein |
| ATE423313T1 (de) * | 1997-04-14 | 2009-03-15 | Arena Pharm Inc | Methode zum identifizieren von modulatoren der zelloberflächenmembranrezeptoren,nützlich zur behandlung von krankheiten |
-
1999
- 1999-07-30 DE DE69940923T patent/DE69940923D1/de not_active Expired - Lifetime
- 1999-07-30 NZ NZ509429A patent/NZ509429A/en not_active IP Right Cessation
- 1999-07-30 IL IL14085899A patent/IL140858A0/xx unknown
- 1999-07-30 CA CA002338543A patent/CA2338543C/en not_active Expired - Fee Related
- 1999-07-30 WO PCT/US1999/017425 patent/WO2000006597A2/en active Application Filing
- 1999-07-30 DK DK99941990T patent/DK1095275T3/da active
- 1999-07-30 EP EP99941990A patent/EP1095275B1/en not_active Expired - Lifetime
- 1999-07-30 AU AU55459/99A patent/AU751080B2/en not_active Ceased
- 1999-07-30 CN CNB998122653A patent/CN1231762C/zh not_active Expired - Fee Related
- 1999-07-30 AT AT99941990T patent/ATE432472T1/de not_active IP Right Cessation
- 1999-07-30 MX MXPA01001176A patent/MXPA01001176A/es unknown
- 1999-07-30 JP JP2000562393A patent/JP2002521681A/ja not_active Ceased
-
2001
- 2001-01-30 NO NO20010509A patent/NO20010509L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU5545999A (en) | 2000-02-21 |
| AU751080B2 (en) | 2002-08-08 |
| MXPA01001176A (es) | 2005-07-25 |
| CN1323396A (zh) | 2001-11-21 |
| JP2002521681A (ja) | 2002-07-16 |
| NZ509429A (en) | 2002-06-28 |
| EP1095275A2 (en) | 2001-05-02 |
| WO2000006597A9 (en) | 2000-07-13 |
| EP1095275B1 (en) | 2009-05-27 |
| NO20010509D0 (no) | 2001-01-30 |
| WO2000006597A2 (en) | 2000-02-10 |
| ATE432472T1 (de) | 2009-06-15 |
| CA2338543A1 (en) | 2000-02-10 |
| WO2000006597A3 (en) | 2000-05-18 |
| DE69940923D1 (de) | 2009-07-09 |
| DK1095275T3 (da) | 2009-09-28 |
| NO20010509L (no) | 2001-03-19 |
| CN1231762C (zh) | 2005-12-14 |
| CA2338543C (en) | 2009-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199801679T2 (xx) | Osteoporoz i�in birle�tirme terapisi. | |
| EP1461061A4 (en) | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS | |
| HK1060519A1 (en) | Compositions containing alpha-2-adrenergic agonist components | |
| DK1199069T3 (da) | Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed | |
| TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
| LU91758I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
| ATE215369T1 (de) | Carbazolanaloge als selektive beta3-adrenergische agonisten | |
| AUPO755097A0 (en) | Receptor agonist and antagonist | |
| ATE247470T1 (de) | Neue substituierte imidazolverbindungen | |
| IS5543A (is) | Nýr G próteintengdur viðtaki | |
| ITMI991964A0 (it) | Derivati benzimidazolonici aventi affinita' mista per i recettori di s erotonina e dopamina | |
| IL142921A0 (en) | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS | |
| ATE218708T1 (de) | Elektrochemischer affinitätsassay | |
| AR020442A1 (es) | Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma | |
| MX2009002787A (es) | Composiciones y métodos para prevenir el cáncer con cupredoxinas. | |
| EP0831871A4 (en) | SIMILAR FACTOR TO RELAXIN, ITS METHODS AND USES | |
| BR0113321A (pt) | Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i | |
| IL140858A0 (en) | Endogenous constitutively activated g protein-coupled orphan receptors | |
| BR0108454A (pt) | Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos | |
| WO2004108887A3 (en) | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | |
| HUP0100115A2 (hu) | Eljárás kóros vágy csökkentésére emlősökben | |
| DK0862627T3 (da) | Neuropeptid Y-Y5 receptor | |
| BR0011261B1 (pt) | composiÇço oral compreendendo perlita, e, uso de perlita. | |
| NO990849L (no) | Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner | |
| DE60139770D1 (de) | Hydantoin derivate mit affinität für somatostatin rezeptoren |